Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 23 | 2025Novo Files HD Oral Sema; Roche Expands US Manufacturing; MetaVia Additional Ph1 Obesity Results; Ypsomed Sells Diabetes Care Business; Biolinq $100M Series C; April CHMP Agenda Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Topics Apr 21 | 2025Medtronic Receives FDA Approval for Simplera + MiniMed 780GPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Topics Apr 17 | 2025Lilly Ph3 Orforglipron T2DM Topline ResultsPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Apr 16 | 2025Abbott Q1 ’25 Earnings Update Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 15 | 2025Zealand Accelerates Hiring & Initiates New Ph2 Petrelintide Study; Merck Licenses Oral Drug Delivery Platform; MetaVia Ph1 Obesity Results; Skye Preclinical Obesity Results Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 14 | 2025Pfizer Discontinues Danuglipron in Obesity; Verve Shares Initial Ph1b HeFH/CAD Data; Novo Warns Against Counterfeit Ozempic; Syntis Announces Preliminary Data in Obesity Purchase Blast
$599
Posted in: Glucose Monitoring, Topics Apr 10 | 2025Dexcom Receives FDA Clearance for G7 15 Day CGMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 10 | 2025Lilly Initiates New Ph1 Eloralintide + Tirzepatide Study and DTC TV Ad; Another Integration with LillyDirect; Biophytis Confirms Ph2 Obesity Study Plans Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 09 | 2025Obesity Spotlight: Roche’s Journey to Commercialization Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 08 | 2025Novo Invests in Brazil Manufacturing Facility; Teladoc Launches Cardiometabolic Health Program Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 07 | 2025Lilly Initiates Ph3 Tirzepatide T1DM Study; AOMs Left Out of Medicare Coverage; Ypsomed and Sidekick Partner for Obesity; GLP-1 Scientists Win Breakthrough PrizePurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 03 | 2025Novo’s Executive Team Changes; knownwell Integrates with LillyDirect; Meitheal Launches Generic Liraglutide; CVS Caremark Partners with Omada Purchase Blast
$599
Posted in: GLP-1RA, Other, Topics Apr 02 | 2025Lilly Sues More Compounders; Inventiva Completes Lanifibranor Ph3 Enrollment Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 01 | 2025Biomea Q4 ‘24 Earnings; Gubra Ph1 GUBamy Trial Updates; Sernova Ph1/2 Cell Pouch Study Updates; Updated SAB Q4 '24 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 31 | 2025Novo, Lilly, and AZ Data at ACC 2025; Vertex T1DM Updates; Palatin Ph2 Obesity Results; Noom Integrates with LillyDirect; SAB Q4 ‘24 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 28 | 2025Novo Buys Oral Obesity Asset from Lexicon; Corbus Ph1 CB1 Trial Update Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 26 | 2025Metsera and Beta Bionics Q4 ’24 Earnings; Viking Oral GLP-1RA Ph2 Trial Update; Vivani Preclinical Data; Dexcom Appoints New CCO Purchase Blast
$599
Posted in: Other, Topics Mar 25 | 2025Merck Enters Licensing Agreement for Oral Lp(a)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 24 | 2025Novo Buys Triple Agonist and Expands Wegovy Savings Program; Biomea Presents Data at ATTD 2025; March CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 21 | 2025ATTD 2025 Key Press Releases (March 21) Purchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
